EUVIMEDEUVIMED entdecken
Crossref

Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2

Bambang Hariwiyanto, Soenarto Sastrowiyoto, Sofia Mubarika, Salugu Masesadji

Oto Rhino Laryngologica Indonesiana · 2011

DOI: 10.32637/orli.v41i1.52 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oto Rhino Laryngologica Indonesiana, 2011. Verfasst von Bambang Hariwiyanto und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nasopharyngeal carcinoma (NPC) is one of the most common among head and neck malignancies, especially in some Asian countries. Epstein-Barr Virus (EBV) is one of the agent causing NPC, expressing many proteins such as Epstein-Barr nucleus antigen (EBNA). Expression of EBNA theoretically influencing therapy KNF outcome.

Purpose

To differentiate therapy result between NPC expressed positive EBNA1 and EBNA2 compared with NPC expressed negative EBNA1 and EBNA2.

Method

Nested case control study toward 28 complete remission NPC patients and 28 partial remission NPC patients post treatment.

Result

There was no significant difference in therapy outcome between NPC with EBNA1 expression =4.90 compared to EBNA1

Zitieren

APA

Hariwiyanto, B., Sastrowiyoto, S., Mubarika, S., & Masesadji, S. (2011). Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2. Oto Rhino Laryngologica Indonesiana. https://doi.org/10.32637/orli.v41i1.52

Vancouver

Hariwiyanto B, Sastrowiyoto S, Mubarika S, Masesadji S. Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2. Oto Rhino Laryngologica Indonesiana. 2011. doi:10.32637/orli.v41i1.52

BibTeX
@article{Hariwiyanto2011,
  author = {Hariwiyanto, Bambang and Sastrowiyoto, Soenarto and Mubarika, Sofia and Masesadji, Salugu},
  title = {Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2},
  journal = {Oto Rhino Laryngologica Indonesiana},
  year = {2011},
  doi = {10.32637/orli.v41i1.52}
}
Kostenlos starten →